Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
    • Dairy Industry
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us

Actiphage shows benefits for quality assurance in milk

Johne's Disease, is a wasting disease caused by MAP. A sensitive test for assessing milk samples would be a useful quality assurance tool.
  • January 26, 2022
  • Dairy industry, Milk Quality Assurance
  • dairy, MAP

Researchers from the Czech Republic (Czechia) assessed the applicability and efficiency of using Actiphage® for rapid detection and quantification of viable MAP in milk samples.

They used the phage-based kit combined with IS900 real-time PCR (qPCR) and the results were published recently in Frontiers in Veterinary Science.

The authors, Monika Beinhauerova and Iva Slana, of the Department of Microbiology and Antimicrobial Resistance at the Veterinary Research Institute in Brno, said: “We demonstrated that Actiphage, in combination with IS900 qPCR, allows rapid and sensitive detection and identification of viable MAP in milk samples with a limit of detection of 1 MAP per 50 ml Milk.

“Using this method, the presence of viable MAP cells was successfully determined in 30.77% of fresh goat, sheep and cow milk samples originating from herds infected with paratuberculosis.”

The researchers also used the Actiphage assay to define the time-lapse aspect of testing naturally contaminated milk and milk filters frozen for various lengths of time by phage-based techniques.

Viable MAP was detected in 13.04% of frozen milk samples and 28.57% of frozen milk filters using Actiphage-qPCR.

They conclude: “The results suggest the ability to detect viable MAP in these samples following freezing for more than one year. The obtained results support the views of the beneficial role of this technology in the control or monitoring of paratuberculosis.”

Application of the Actiphage® Assay to Detect Viable Mycobacterium avium subsp. paratuberculosis Cells in Fresh Sheep and Goat Milk and Previously Frozen Milk and In-Line Milk Filters
Monika Beinhauerova and Iva Slana. Front. Vet. Sci., 11 October 2021 | https://doi.org/10.3389/fvets.2021.752834

Share:

Related posts

Loading...
Johnes Disease testing service

Is there Johne’s Disease in the herd? PBD’s new testing service provides yes/no answer

April 7, 2022
A new rapid testing service from PBD Biotech will enable farmers to find out in days if a bulk milk or blood sample contains MAP, the bacteria that causes Johne's Disease an economically devastating disease.
Johnes Disease testing service

Is there Johne’s Disease in the herd? PBD’s new testing service provides yes/no answer

April 7, 2022
A new rapid testing service from PBD Biotech will enable farmers to find out in days if a bulk milk...
Ben Swift with cows

11 September 2019

PBD Biotech to feature in Innovation Zone at UK Dairy Day 2019

August 8, 2019
Dairy farmers and producers interested in implementing an effective disease management strategy for bovine Tuberculosis (bTB) and Johne’s disease will be able to find out more at PBD Biotech’s stand in the Innovation Zone at UK Dairy Day 2019 on...
Ben Swift with cows

11 September 2019

PBD Biotech to feature in Innovation Zone at UK Dairy Day 2019

August 8, 2019
Dairy farmers and producers interested in implementing an effective disease management strategy for bovine Tuberculosis (bTB) and Johne’s disease will...
Actiphage mycobacterial diagnostic

Dairy-Tech Royal Innovation Dairy Award announces Actiphage as finalist

January 31, 2019
PBD Biotech is delighted that its novel Actiphage® testing technology has been shortlisted as a finalist for the Royal Dairy Innovation Award, to be presented at this year’s Dairy-Tech (6 February 2019).
Actiphage mycobacterial diagnostic

Dairy-Tech Royal Innovation Dairy Award announces Actiphage as finalist

January 31, 2019
PBD Biotech is delighted that its novel Actiphage® testing technology has been shortlisted as a finalist for the Royal Dairy...

Interest in Actiphage diagnostic from world leading milk industry

November 26, 2018
The UK Government Department of International Trade (DIT) has invited PBD Biotech to profile their Actiphage® diagnostic for mycobacterial disease as part of their annual trade delegation to India – the world’s second largest producer of milk.

Interest in Actiphage diagnostic from world leading milk industry

November 26, 2018
The UK Government Department of International Trade (DIT) has invited PBD Biotech to profile their Actiphage® diagnostic for mycobacterial disease...
1 2 Next »

developers of phage-based diagnostics

Contact Us

Registered Company Address
Grosvenor St Paul’s
Grosvenor House
11 St Paul’s Square
Birmingham
B3 1RB
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

More reasons to invest in better diagnostics for #tuberculosis 1.6 million preventable deaths and increased pressure on the few treatments available. #EndTB

Read More
PBD Biotech

Delighted Dr Marie Roskrow is the new Chair @PBDBiotech to support development of our rapid TB diagnostic. A physician-scientist she brings expertise from @KinomicaLtd @ImevaX along with Patrys Limited, METALINEAR LIMITED, ArcticZymes Technologies

Read More
PBD Biotech

Testing 4 tuberculosis gained renewed attention in 2022 reports @360DxNews Highlighting $30m funding @UNITAID for @FINDdx also @PBDBiotech gaining $2.9M for its blood-based test to predict which individuals with latent TB will progress to active disease

Read More